This Ruth L. Kirschstein National Research Service Award Postdoctoral Research Training Grant renewal application is submitted in response to Program Announcement PA-16-152 for applications to provide institutional T32 awards to train young researchers who will become independent investigators conduting research that addresses important problems in human health. The application requests continued resources to support four physician/scientists each year with MD or MD/PhD degrees who receive mentored research that focuses on the etiology, pathogenesis, and treatment of pediatric malignancies. The overall objective of this T32 program is to train new investigators who will improve the care of children with cancer. The rationale for the program is based on the substantial burden of pediatric cancer in the United States and the well- documented and critical need to provide mentored career development support for young physicians that will enable them to become fully independent and productive laboratory researchers. As such, they will be poised to improve the health of children with cancer throughout the world by bringing state-of-the-art expertise to bear on problems such as inherited predispostions, environmental factors, the toxic and relatively non-specific nature of current therapies, and long-term adverse effects of mutagenic treatments. The design of this program involves harnessing the expertise of world-class research scientists who serve as mentors for interdisiciplinary training. We have successfully implemented distinct trainng tracks for laboratory-based and clincial/translational investigators. We believe that the progress of this T32 program since its inception in 2007 demonstrates tht UCSF has the vision, experience, and infrastructure to train the next generation of leaders in childhood cancer research. In this renewal application, we provide evidence that the Department or Pediatrics and Division of Hematology/Oncology together with the broader UCSF research community comprise an exceptional environment for preparing young physicians for productive careers as independent investigators the field of childhood cancer. This application describe a comprehensive plan for idnetifying, training, and mentoring these individuals. This application is directly relevant to human health as it requests funds to support mentored career development for outstanding young physician/investigators who will become independent researchers in the field of childhood cancer. Programs like this one represent an investment in the future of public health as the researchers who are trained through this award will be equipped to harness state-of-the-art research techniques to attack a formidable health problem in the pediatric population. The long-term outcome of intensive and innovative training provided by this T32 award will be effective new treatments for childhood cancers.
PRPOJECT NARRATIVE This competitive renewal application of a Ruth L. Kirschstein National Research Service Award Postdoctoral Research Training Grant has the overall goal of training physicians for independent research careers investigating the etiology, pathogenesis, and treatment of pediatric cancer. We believe that the outstanding research faculty, institituonal resources, educational programs, and pool of highly qualified trainees at UCSF result in an outstadning environment for achieving this goal.
|Kumar, Prerna; Gill, Ryan M; Phelps, Andrew et al. (2018) Surveillance Screening in Li-Fraumeni Syndrome: Raising Awareness of False Positives. Cureus 10:e2527|
|Kline, Cassie; Felton, Erin; Allen, I Elaine et al. (2018) Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis. J Neurooncol 137:103-110|
|Tolbert, Vanessa P; Matthay, Katherine K (2018) Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res 372:195-209|
|Wang, David; Quiros, Jason; Mahuron, Kelly et al. (2018) Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. Cell Rep 23:3262-3274|
|Dvorak, Christopher C; Satwani, Prakash; Stieglitz, Elliot et al. (2018) Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatr Blood Cancer 65:e27034|
|Forester, Craig M; Zhao, Qian; Phillips, Nancy J et al. (2018) Revealing nascent proteomics in signaling pathways and cell differentiation. Proc Natl Acad Sci U S A 115:2353-2358|
|Stieglitz, Elliot; Mazor, Tali; Olshen, Adam B et al. (2017) Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun 8:2127|
|Vo, Kieuhoa T; Karski, Erin E; Nasholm, Nicole M et al. (2017) Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. Oncotarget 8:23851-23861|
|Kline, Cassie N; Packer, Roger J; Hwang, Eugene I et al. (2017) Case-based review: pediatric medulloblastoma. Neurooncol Pract 4:138-150|
|Dvorak, Christopher C; Puck, Jennifer M; Wahlstrom, Justin T et al. (2017) Neurologic event-free survival demonstrates a benefit for SCID patients diagnosed by newborn screening. Blood Adv 1:1694-1698|
Showing the most recent 10 out of 95 publications